• Call(WhatsApp Us)

    +8615360806100
  • Email Us

    cherry@laeyo.com
  • 广州市花都区花山镇华辉路18号

    微观化妆品创意产业园E栋整栋

Out-of-Specification Viscosity in Face Cream: What Should Happen Before Batch Release?

A viscosity result outside the approved specification on a face cream batch is a release blocker, not a paperwork nuisance. Viscosity drives how the cream fills, how the jar or pump performs, how the…

Category: Body Care Sourcing Guides • Author: laeyo • Published: 2026-11-16 • Views: 16

A viscosity result outside the approved specification on a face cream batch is a release blocker, not a paperwork nuisance. Viscosity drives how the cream fills, how the jar or pump performs, how the product spreads, and whether the texture still matches the sample the brand approved. When a batch fails the viscosity specification, the buyer-facing question is narrow and practical: what has to be closed, documented, and signed off before that batch can legally and commercially ship? This guide walks sourcing managers and brand owners through the sequence a manufacturer should follow — hold, dual investigation, impact assessment, rework risk review, and a controlled batch release decision — and tells you exactly which documents to request at each step.

1. Start With the Specification Itself: Is the Failure Real?

Before an out-of-specification (OOS) investigation means anything, the specification has to be unambiguous. A viscosity limit written as “40,000–60,000 mPa·s” without a method is not a specification — it is an invitation to dispute. The approved spec for a face cream should define the test method ID, instrument and spindle, rotational speed, temperature, equilibration time, and sampling point (bulk vs. finished pack).

Control item What the spec should state Frequency Critical?
Appearance Match against the controlled Golden sample (colour, gloss, uniformity) Each batch Yes
pH SKU-defined range, defined dilution and temperature Each batch Yes
Viscosity SKU-defined range + method ID, spindle, rpm, temperature, equilibration time Each batch Yes
Microbiology Per target-market limits (e.g., US, EU, China differ) Each batch Yes
Packaging compatibility Pump dispensing force, jar torque, label adhesion, fragrance–plastic interaction Per SKU / on change Yes

If the result is outside the limit, it is an OOS and the batch is frozen. If the result is inside the limit but drifting toward the edge — for example a historical centre of 50,000 mPa·s against a 40,000–60,000 range, with the current batch at 41,500 — that is an out-of-trend (OOT) signal. It is not automatically escalated to OOS, but it still warrants a documented trend review, because the next batch may cross the lower limit. A manufacturer that only reacts to OOS and never charts trends is a manufacturer you will eventually have a recall conversation with.

2. The First 24 Hours: Hold First, Investigate Second

The correct first action is a hold, not a retest. The batch, the retained samples, and any finished goods already packed from that bulk should be placed on hold while two investigations run in parallel:

  • Laboratory investigation — was it a testing error? Wrong spindle, insufficient equilibration, sample taken from a non-homogeneous area, instrument calibration out, or a transcription error in the certificate of analysis.
  • Manufacturing investigation — was it a process or material cause? Emulsifier or thickener lot variation, water phase temperature, homogenisation speed or time, hold time before filling, cooling rate, or a raw material substitution.
  • Impact-lot assessment — which other batches used the same raw material lots, the same equipment train, or the same process window?

Only after both investigations are documented should a retest be considered, and only under a pre-approved retest plan that states how many retests, on which sample (original or retained), by whom, and what happens if the retest also fails. Retesting until the number looks acceptable is not an investigation.

3. Rework and Reprocessing: The Highest-Risk Resolution Path

Thinning or thickening a failed cream back into specification is possible, but it is a formal, risk-assessed activity — not a production-floor adjustment. Before any rework or reprocessing is approved, the manufacturer should complete and document a risk assessment covering:

  • Stability impact — does the added shear, heat, or diluent change the emulsion’s shelf life or cause later phase separation?
  • Microbiological impact — does reworking open the bulk to additional handling exposure, and does the preservative system still hold?
  • Performance impact — does the reworked cream still match the approved Golden sample for spreadability, absorption, and after-feel?
  • QA approval — a named quality approver signs the rework instruction, with the batch record updated accordingly.

Ask directly: “Has QA approved this rework in writing, and does the approval reference the stability and micro assessments?” If the answer is no, the batch is not reworkable — it is a reject.

4. Before Batch Release: The Controlled Decision Pack

Batch release is a decision, not an automatic consequence of tests passing. For a face cream in any market, the release decision should be traceable to a defined input set:

  • Raw material and packaging material release records
  • Executed batch record and in-process controls (temperature, homogenisation, pH, viscosity at bulk stage)
  • Bulk and finished-goods test results, linked to result IDs
  • Microbiology results against the target-market limits
  • Deviation log — no open deviations affecting the batch
  • OOS/OOT log — no open investigations affecting the batch
  • Line clearance and packaging records
  • Retained sample confirmed available and stored under controlled conditions, with the formula version referenced
  • Label and claims version check for the destination market

Commercial pressure does not override a quality hold. If a sales deadline is cited as the reason a batch is being released, treat that as a warning sign, not a reassurance.

5. What to Request From the Manufacturer

Send this list as-is. Every item has a deliverable attached to it, which is what makes the request answerable rather than negotiable.

  • OOS investigation report — with lab and manufacturing sections, root cause conclusion, and CAPA.
  • Retest plan, approved before retesting — including sample identity and acceptance logic.
  • Trend chart for viscosity across the last 10–20 batches of the same SKU — to distinguish an isolated failure from a drift.
  • Impact-lot list — all batches sharing the implicated raw material lots or equipment.
  • Rework/reprocess risk assessment — stability, micro, and performance sections, plus QA signature.
  • Stability data supporting the disposition — at minimum accelerated data and any available real-time data.
  • Packaging compatibility confirmation — pump dispensing force or jar torque tested with the actual bulk viscosity, plus label adhesion.
  • Retained sample photographs and inspection record for the failed batch and the Golden reference.
  • Certificate of Analysis that matches the current specification version, not a superseded one.
  • Signed batch release record showing the disposition (release, hold, reject, or rework) and the approver.

6. Realistic Timeline

Phase Buyer action Manufacturer action Evidence output
Day 0–1 Confirm the hold in writing; stop any shipment Freeze batch, retain samples, and affected finished goods Hold notice with batch ID and scope
Day 1–3 Request the investigation plan and retest plan Run laboratory investigation; verify method and instrument Lab investigation record, calibration records
Day 1–5 Ask which raw material lots and lines are implicated Run manufacturing investigation and impact-lot review Manufacturing investigation report, impact-lot list
Day 3–7 Decide: reject, rework, or continue investigation Complete rework risk assessment if rework is proposed Signed risk assessment with stability/micro/performance sections
Week 2–4 Review bridging data before agreeing to release Stability and micro checks on reworked bulk; packaging re-check Updated stability and micro results, packaging compatibility report
On closure Confirm documentation is complete before payment or shipment Issue final disposition and release record COA, batch release record, CAPA, retained sample confirmation

7. Common Failure Modes and How to Prevent Them

“It passed on retest” — with no investigation

Root cause: retesting used as a substitute for root-cause analysis. Prevention: require an approved retest plan and a written investigation before any retest is accepted. Request: the lab investigation record and the retest plan approval.

Viscosity passes, but the pump no longer dispenses

Root cause: packaging compatibility was validated at the target viscosity centre, and the batch sits at the lower edge of the range, changing flow behaviour through the pump. Prevention: require dispensing-force and torque testing across the full viscosity range, not just at the midpoint. Request: a packaging compatibility report linking bulk viscosity to pump output and jar torque.

Batch released with an open deviation or a mismatched spec version

Root cause: documentation control failure — the COA references an older specification, or the release record omits an open OOS. Prevention: require the release record to reference result IDs, deviation IDs, and the current spec version. Request: the signed release record plus the specification version history.

Reworked cream separates on the shelf three months later

Root cause: rework approved without a stability assessment. Prevention: no rework without a QA-approved risk assessment that includes accelerated stability. Request: the stability protocol and results for the reworked bulk.

The same viscosity failure recurs on the next batch

Root cause: a downward drift was visible in trend data but never reviewed as an OOT signal. Prevention: require trend charts and documented OOT reviews, not just pass/fail reporting. Request: the last 10–20 batch trend chart and any OOT review records.

No retained sample available when a complaint arrives

Root cause: retain sample policy not applied per batch, or storage conditions not controlled. Prevention: make retain sample confirmation a release prerequisite. Request: the retain sample log with storage conditions and formula version.

8. Do Not Cut: Red Lines

  • Never release a batch with an open OOS or OOT investigation affecting it.
  • Never accept a retest-only closure without a documented root cause.
  • Never approve rework without stability, micro, and performance assessment plus QA signature.
  • Never skip retain samples — they are your only retrospective evidence.
  • Never accept a COA that does not match the current specification version.
  • Never let a shipping deadline determine a quality disposition.

Frequently Asked Questions

Is an out-of-trend result treated the same as an out-of-specification result?

No. An OOT result is still within specification, so it does not automatically escalate to OOS. It does, however, trigger a documented trend review to find the cause of the drift — such as raw material degradation or microbial activity — and to assess whether the product will remain reliable across its shelf life.

Can the manufacturer simply adjust viscosity and release the batch?

Only through a formally approved rework or reprocessing route. That requires a risk assessment covering stability, microbiological, and performance impact, and it requires quality approval before the adjustment is made. Without that, the batch should be rejected.

How can a buyer verify batch-to-batch consistency if full efficacy testing isn’t run every batch?

Through a combination of per-batch release parameters (appearance, pH, viscosity, micro), process proxies (raw material identity, active dosage, temperature, shear, hold time), comparison against a controlled Golden sample, and periodic performance verification. Revalidation is triggered by formula, process, or raw material changes.

What single document should a buyer ask for first?

The OOS investigation report, because it shows whether the manufacturer investigated both the laboratory and the manufacturing process, and whether the conclusion is supported by data or by convenience.

Informational only, not legal advice. Market-specific labelling, registration, and claims requirements should be confirmed with your regulatory specialist for each destination market.

Need a manufacturing partner who will hand over the investigation record, trend chart, and release documentation without being asked twice? Request a Quote and include your target market, SKU list and formats, positioning, packaging direction, and timeline so the response comes back with real lead times rather than a generic reply.

Hi, I'm your LAEYO representative, hope you like this blog post.

With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.

  • Our team will answer your inquiries within 8 hours.
  • Your information will be kept strictly confidential.

Request received

Thanks — we’ve received your request. Our team will follow up shortly. we typically reply within 8 hours (often sooner).